Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR113945 · 4 trials · 2 indications
Examination of skin/soft tissue of injected knee: Any reaction is classified as erythema, edema, pain, hematoma and graded none, mild, moderate or severe. Examination of knee joint of injected knee: Any reaction is classified as effusion/worsening of effusion, warmth and pain.
Any reaction is classified as erythema, oedema, pain, papulae, haematoma and graded none, mild, moderate or severe.
Any reaction is classified as effusion/worsening of effusion, warm and pain.
| Arm | Type | Description |
|---|---|---|
| SAR113945 | EXPERIMENTAL | TDU11685 selected dose |
| Placebo | PLACEBO_COMPARATOR | - |
| Dose 1 | EXPERIMENTAL | SAR113945 low dose |
| Dose 2 | EXPERIMENTAL | SAR113945 medium dose |
| Dose 3 | EXPERIMENTAL | SAR113945 high dose |
| SAR113945 - Dose 1 | EXPERIMENTAL | - |
| SAR113945 - Dose 2 | EXPERIMENTAL | - |
| SAR113945 - Dose 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SAR113945 | DRUG | Pharmaceutical form:Injection Route of administration: Intra-articular |
| placebo | DRUG | Pharmaceutical form:Injection Route of administration: Intra-articular |
Inclusion criteria : Diagnosis of primary knee osteoarthritis, based upon the following: * X-ray or Magnetic Resonance Imaging (MRI) evidence within the last 6 months for joint space narrowing and osteophyte formation * Patients will be Kellgren and Lawrence classification II/III, and total Wester...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
SAR113945 is an investigational small molecule being developed for knee osteoarthritis and osteoarthritis. It is administered intra-articularly, meaning directly into the knee joint. The drug is currently in clinical development and has not been approved by regulatory authorities.
SAR113945 is being developed by Sanofi, a multinational pharmaceutical company traded on the stock exchange under the ticker symbol SNY. Sanofi has conducted multiple clinical trials to evaluate the safety, tolerability, and pharmacokinetics of this investigational drug in patients with knee osteoarthritis.
SAR113945 is in Phase 2 clinical development. The drug has completed three Phase 1 trials and one Phase 2 trial, all of which are finished. No active trials are currently ongoing for SAR113945, and it remains an investigational agent that is not yet approved for any use.
SAR113945 has been studied in four completed clinical trials. These include NCT01113333, NCT01463488, and NCT01511549, which were Phase 1 studies, and NCT01598415, a Phase 2 study. The trials enrolled a total of 178 patients with knee osteoarthritis or osteoarthritis, conducted in Germany and Japan.
SAR113945 is administered via intra-articular injection, meaning it is injected directly into the knee joint. This route of administration is used in the clinical trials for knee osteoarthritis to deliver the drug locally to the affected area. The drug is being tested as a potential treatment for osteoarthritis.
SAR113945 is the sole name provided for this investigational drug, with no alternative names listed. It is a distinct small molecule being developed by Sanofi for knee osteoarthritis. As it is still in clinical development, it does not have a brand name or generic name yet.